Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 154

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 154
---
 have not yet registered certain of our trademarks in all of our potential markets. As we apply to register our unregistered trademarks in the U.S. and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. For example, our application to register the “Rewell” trademark in Colombia was rejected in 2022, was denied by the relevant governmental authority because it was deemed confusingly similar to RECELL, a trademark previously registered by AVITA MEDICAL LTD in related, though not identical, products and services. On August 31, 2022, an appeal was filed to contest this decision, but it was also rejected, which prohibits us from using the trademark in that jurisdiction and may continue to do so in the future as we continue the planned expansion of the “Rewell” trademark. In addition, opposition or cancellation proceedings may 56 be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In certain countries outside of the U.S., trademark registration is required to enforce trademark rights. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. Any future patents covering our products and services could be found invalid or unenforceable if challenged. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our future patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in the U.S. and abroad. We or our collaborators may be subject to a third -partypre -issuancesubmission of prior art to the United States Patent and Trademark Office (“USPTO”) or be involved in opposition, derivation, revocation, reexamination, inter partes review, post -grantreview or interference or other similar proceedings challenging our or our collaborators’ patent rights. An adverse decision in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our drugs or other technologies and compete directly with us, without payment to us or result in our inability to manufacture or commercialize products without infringing third -partypatent rights. Additionally, if we and our licensing partners initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our products or technologies, the defendant could counterclaim that the patent covering our product